Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel in Dedifferentiated Liposarcoma
NCT01913652Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2014
- Primary completion
- Dec 2020
- Modality
- Allosteric Modulators
- Countries
- 4
01
Overview
A Phase 2 trial of cabazitaxel in dedifferentiated liposarcoma (DDL), sponsored by European Organisation for Research and Treatment of Cancer. Started Oct 2014; status: completed.
02
Drugs
cabazitaxel
03
Conditions
dedifferentiated liposarcoma (DDL)
Beyond the preview
Go deeper on NCT01913652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01913652.